HBV and HCV Therapy
Author Information
Author(s): Lampertico Pietro, Aghemo Alessio, Viganò Mauro, Colombo Massimo
Primary Institution: Fondazione IRCCS Maggiore Hospital, Università di Milano
Hypothesis
The study investigates the effectiveness of different antiviral therapies for chronic hepatitis B and C.
Conclusion
The study concludes that long-term nucleos(t)ide analogue therapy is effective for most patients with chronic hepatitis B, while pegylated interferon combined with ribavirin is the standard treatment for chronic hepatitis C, achieving a sustained virological response in nearly 65% of patients.
Supporting Evidence
- Chronic hepatitis B affects about 400 million people globally.
- Interferon therapy inhibits HBV replication in one third of patients.
- Pegylated interferon combined with ribavirin has become the standard treatment for chronic hepatitis C.
Takeaway
This study shows that there are effective treatments for hepatitis B and C, which can help people live healthier lives. Some medicines work better for different types of hepatitis.
Methodology
The study reviews various antiviral therapies and their effectiveness in treating chronic hepatitis B and C.
Limitations
The study does not provide specific data on the long-term safety and resistance issues associated with the therapies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website